ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2722

Cyclic Phosphatidic Acid (CPA) Suppresses Expression of Cartilage Degrading Enzymes Such As MMP-3, MMP-13 and Adamts-4 in Inflammatory Synovial Fibroblasts and Articular Chondrocytes Induced By IL-1 Beta and/or TNF ALFA

Ikuko Masuda1,2, Kodo Okada3, Hisashi Yamanaka1 and Shigeki Momohara1, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Rheumatology, Jyujyo Takeda Rehabilitation Hospital, Kyoto, Japan, 3SANSHO, Co. Ltd., Tokyo, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: cartilage, chondrocytes, degenerative arthritis, inflammatory cytokines and synovial cells, synovial fluid

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Cyclic phosphatidic acid (cPA) is one of bioactive lipid, has been implicated as an mediator of various biological effects including inhibitory effects of proliferation, invasion and metastasis of cancer cells. We have previously confirmed that cPA stimulated HAS-2 production on human osteoarthritic chondrocytes and synovial fibroblasts (SFs) in vitro. Furthermore, intra-articular administration of cPA has shown its suppressing effect of pain, swelling, and articular cartilage destruction in rabbit experimental osteoarthritis. We have shown that cPA might had direct inhibitory effect of cartilage degrading enzymes on rheumatoid synovial fibroblasts (SFs) in vitro. Inflammatory arthritis such as rheumatoid arthritis and early stage of OA involves synovial inflammation and subsequent production of cartilage degrading enzymes. cPA is naturally occurring mediator even exists in human serum. cPA may be possible another therapeutic option for degenerative arthritis.  The aim of this study was to evaluate the direct effects of cPA on cartilage matrix degrading enzymes using SFs and articular chondrocytes under influence of inflammatory cytokines. 

Methods: In vitro studies were performed using SFs and chondrocytes obtained from arthritis patients at joint replacement surgery.  cPA 0-25 μM was added to cell cultures and effects of cPA on ADAMTS-4, -5, MMP-3, -13, TIMP-3 expression were assessed by real time PCR using specific primers to corresponding genes. SFs or chondrocytes were also cultured with IL-1β (2.5ng/ml) and/or TNF-α (10 ng/ml), to study attenuated effect of cPA. Beta-actin was used as endogenous expression control for PCR. Newly synthesized MMP-3, -13, TIMP-3 from SFs or chondrocytes in cultured media were measured by sandwich ELISA.

Results: cPA itself repressed cartilage degrading enzymes, ADAMTS-4, ADAMTS-5, MMP-3, and MMP-13 expression in both SFs and chondrocytes was all repressed by low dose of cPA, even after these expressions was stimulated by cytokines. Expression of these enzymes were repressed more in chondrocytes by cPA. ELISA results also confirmed the inhibitory effect of cPA on MMP-3, MMP-13, and PGE2 production.

Conclusion: The in vitro results confirmed that cPA had suppressing effect of cartilage degrading enzymes on SFs and chondrocytes, supports the hypothesis that cPA might have played direct role to suppress inflammation and also protect articular cartilage in arthritic condition. Molecular mechanism of cPA to prevent cartilage degradation remains to be elucidated, however, further study should be warranted for cPA as a novel candidate for therapeutic agent of arthritis.


Disclosure: I. Masuda, None; K. Okada, None; H. Yamanaka, Abbott, AbbVie, Asahikasei , Astellas, AstraZeneca, Bristol- Myers Squib, Chugai, Daiichi Sankyo, Eisai, GlaxoSmithKline, Janssen, Mitsubishi Tanabe, MSD, Nippon Kayaku, Pfizer, Santen, Taishotoyama, Takeda, Teijin, 2,Abbott, AbbVie, Astellas, AstraZeneca, Bristol-Myers Squib, Chugai, Daiichi Sankyo, Eisai, Mitsubishi Tanabe, Nippon Kayaku, Pfizer, Takeda, Teijin, 5,Abbott, AbbVie, Astellas, Bristol-Myers Squib, Chugai, Eisai, Mitsubishi Tanabe, Pfizer, Takeda, Teijin.S., 8; S. Momohara, AbbVie, 2,Asahi Kasei, 2,Bristol Myers Squibb, 2,Chugai, 2,Daiichi Sankyo, 2,Eisai, 2,Mitsubishi Tanabe, 2,Nakashima Medical Co., Ltd., 2,Santen Pharmaceutical Co., Ltd., 2,Taisho Toyama Pharmaceutical Co. Ltd, 2,Takeda, 2.

To cite this abstract in AMA style:

Masuda I, Okada K, Yamanaka H, Momohara S. Cyclic Phosphatidic Acid (CPA) Suppresses Expression of Cartilage Degrading Enzymes Such As MMP-3, MMP-13 and Adamts-4 in Inflammatory Synovial Fibroblasts and Articular Chondrocytes Induced By IL-1 Beta and/or TNF ALFA [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/cyclic-phosphatidic-acid-cpa-suppresses-expression-of-cartilage-degrading-enzymes-such-as-mmp-3-mmp-13-and-adamts-4-in-inflammatory-synovial-fibroblasts-and-articular-chondrocytes-induced-by-il-1-b/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cyclic-phosphatidic-acid-cpa-suppresses-expression-of-cartilage-degrading-enzymes-such-as-mmp-3-mmp-13-and-adamts-4-in-inflammatory-synovial-fibroblasts-and-articular-chondrocytes-induced-by-il-1-b/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology